Home > Back to Publisher > Report Information

U.S. Pulmonary Arterial Hypertension Markets

Frost & Sullivan
December 12, 2006
SKU: MC1461613

Abstract Table of Contents Related Reports

Countries covered: United States

Research Overview

This Frost & Sullivan research service entitled U.S. Pulmonary Arterial Hypertension Markets provides a detailed analysis of the competitive structure, market forecasts, and market share analysis. In this research, Frost & Sullivan's expert analysts thoroughly examine the class I, class II, class III, and class IV PAH therapy markets.

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:

Total U.S. PAH therapy
Class I PAH therapy
Class II PAH therapy
Class III PAH therapy
Class IV PAH therapy

Market Overview

"Big Pharma" and Biotechnology Companies Boost U.S. Pulmonary Arterial Hypertension Markets

The U.S. pulmonary arterial hypertension (PAH) markets have been growing due to the launch of new therapies as well as keen interest shown by "Big Pharma" and biotechnology companies. A small patient population notwithstanding, the market is expected to grow rapidly. "The development of a strong clinical pipeline with two major launches in 2007, and improvement in diagnosis rates are likely to drive market growth," says the analyst of this research service.

The number of treatment options available for this condition has grown considerably over the past few years with new therapies expected. The granting of orphan drug status has encouraged the development of drugs, which would have been cost-prohibitive and unprofitable under normal circumstances. "Big Pharma" companies are focusing on this therapeutic area despite the orphan drug status. With increasing awareness of the disease and introduction of better treatment options, diagnosis rates are expected to rise further.

In-licensing Deals and Mergers and Acquisitions Spur Strong Growth

An increase in in-licensing and M&A deals in the PAH markets is also leveraging growth. "The market has drawn interest from "Big Pharma" and biotechnology companies partly due to the high reimbursement rates and average revenue per patient," states the analyst. Therefore, companies are looking to enter into the market through mergers and acquisitions or licensing of clinical stage products.

The key competitive factors include efficacy, convenience of dosing, and side effect profiles of therapies. The progression of PAH is rapid and the mortality rates are extremely high with most patients surviving for less than 3-4 years post diagnosis. Hence, the efficacy of a drug to slow down the progression of the disease, coupled with convenience of dosing is the prime competitive factor.

1. Executive Summary
      1. Executive Summary
              1. Executive Summary

2. Total U.S. Pulmonary Hypertension Markets
      1. Market Overview
              1. Introduction
              2. Market Segmentation
              3. Research Methodology
      2. Market Forecasts
              1. Patient Forecasts
              2. Pricing Forecasts
              3. Revenue Forecasts
      3. Competitive Analysis
              1. Competitive Structure
              2. Market Share Analysis
              3. Product Pipeline

3. U.S. Class I Pulmonary Arterial Hypertension Market
      1. Market Overview
              1. Introduction
              2. Market Engineering Measurements
      2. Market Forecasts
              1. Patient Forecasts
              2. Pricing Forecasts
              3. Revenue Forecasts
      3. Competitive Analysis
              1. Competitive Structure
              2. Market Share Analysis

4. U.S. Class II Pulmonary Arterial Hypertension Market
      1. Market Overview
              1. Introduction
              2. Market Engineering Measurements
      2. Market Forecasts
              1. Patient Forecasts
              2. Pricing Forecasts
              3. Revenue Forecasts
      3. Competitive Analysis
              1. Competitive Structure
              2. Market Share Analysis

5. U.S. Class III Pulmonary Arterial Hypertension Market
      1. Market Overview
              1. Introduction
              2. Market Engineering Measurements
      2. Market Forecasts
              1. Patient Forecasts
              2. Pricing Forecasts
              3. Revenue Forecasts
      3. Competitive Analysis
              1. Competitive Structure
              2. Market Share Analysis

6. U.S. Class IV Pulmonary Arterial Hypertension Market
      1. Market Overview
              1. Introduction
              2. Market Engineering Measurements
      2. Market Forecasts
              1. Patient Forecasts
              2. Pricing Forecasts
              3. Revenue Forecasts
      3. Competitive Analysis
              1. Competitive Structure
              2. Market Share Analysis

7. Decision Support Databases
      1. Disease Incidence
              1. HIV Prevalence
              2. AIDS Incidence
              3. Coronary Heart Disease Prevalence
              4. Hypertension Prevalence

List of Figures

Chapter 2

Total Pulmonary Arterial Hypertension Market: Patient Forecasts (U.S.), 2003-2013
Total Pulmonary Arterial Hypertension Market: Pricing Forecasts (U.S.), 2003-2013
Total Pulmonary Arterial Hypertension Market: Revenue Forecasts (U.S.), 2003-2013
Total Pulmonary Arterial Hypertension Market: Competitive Structure (U.S.), 2006
Total Pulmonary Arterial Hypertension Market: Revenue Market Share by Product (U.S.), 2003-2013
Total Pulmonary Arterial Hypertension Market: Revenue Market Share by Product Type (U.S.), 2003-2013
Total Pulmonary Arterial Hypertension Market: Revenue Market Share by PAH Class (U.S.), 2003-2013
Total Pulmonary Arterial Hypertension Market: Patient Market Share by PAH Class (U.S.), 2003-2013

Chapter 3

Class I Pulmonary Arterial Hypertension Market: Patient Forecasts (U.S.), 2003-2013
Class I Pulmonary Arterial Hypertension Market: Pricing Forecasts (U.S.), 2003-2013
Class I Pulmonary Arterial Hypertension Market: Revenue Forecasts (U.S.), 2003-2013
Class I Pulmonary Arterial Hypertension Market: Competitive Structure (U.S.), 2006
Class I Pulmonary Arterial Hypertension Market: Revenue Market Share by Product (U.S.), 2003-2013
Class I Pulmonary Arterial Hypertension Market: Revenue Market Share by Product Type (U.S.), 2003-2013

Chapter 4

Class II Pulmonary Arterial Hypertension Market: Patient Forecasts (U.S.), 2003-2013
Class II Pulmonary Arterial Hypertension Market: Pricing Forecasts (U.S.), 2003-2013
Class II Pulmonary Arterial Hypertension Market: Revenue Forecasts (U.S.), 2003-2013
Class II Pulmonary Arterial Hypertension Market: Competitive Structure (U.S.), 2006
Class II Pulmonary Arterial Hypertension Market: Revenue Market Share by Product (U.S.), 2003-2013
Class II Pulmonary Arterial Hypertension Market: Revenue Market Share by Product Type (U.S.), 2003-2013

Chapter 5

Class III Pulmonary Arterial Hypertension Market: Patient Forecasts (U.S.), 2003-2013
Class III Pulmonary Arterial Hypertension Market: Pricing Forecasts (U.S.), 2003-2013
Class III Pulmonary Arterial Hypertension Market: Revenue Forecasts (U.S.), 2003-2013
Class III Pulmonary Arterial Hypertension Market: Competitive Structure (U.S.), 2006
Class III Pulmonary Arterial Hypertension Market: Revenue Market Share by Product (U.S.), 2003-2013
Class III Pulmonary Arterial Hypertension Market: Revenue Market Share by Product Type (U.S.), 2003-2013

Chapter 6

Class IV Pulmonary Arterial Hypertension Market: Patient Forecasts (U.S.), 2003-2013
Class IV Pulmonary Arterial Hypertension Market: Pricing Forecasts (U.S.), 2003-2013
Class IV Pulmonary Arterial Hypertension Market: Revenue Forecasts (U.S.), 2003-2013
Class IV Pulmonary Arterial Hypertension Market: Competitive Structure (U.S.), 2006
Class IV Pulmonary Arterial Hypertension Market: Revenue Market Share by Product (U.S.), 2003-2013
Class IV Pulmonary Arterial Hypertension Market: Revenue Market Share by Product Type (U.S.), 2003-2013

Chapter 7

Decision Support Database: Prevalence of HIV in ’000 (World), 1999-2006
Decision Support Database: AIDS Reported Cases (World), 1999-2006
Decision Support Database: Prevalence of Coronary Heart Disease in Million (World), 1999-2006
Decision Support Database: Prevalence of Hypertension in Million (World), 1999-2006

More United States Respiratory/Pulmonary Reports

Epidemiology: COPD - Aging population and stable smoking rates to raise case numbers by Datamonitor
Introduction In 2010, Datamonitor estimates that there were about 69.5 million total prevalent cases of chronic obstructive pulmonary disease (COPD) in people aged over 40 in ...

Cystic Fibrosis by Global Industry Analysts
This report analyzes the US market for Cystic Fibrosis in Millions of US$. Annual estimates and forecasts are provided for the period of 2007 through ...

U.S. Sleep Apnea Diagnostic and Therapeutic Devices Markets by Frost & Sullivan
This research service analyzes market trends in the U.S. sleep apnea diagnostic and therapeutic devices market since 2005, predicts future changes in market measurements through ...

Nosocomial Infections: Market Impact on Diagnostics and Therapeutics: (MRSA, HAP, C. diff and other Hospital Acquired Infections) by Kalorama Information
A nosocomial, or hospital-acquired, infection is a new infection that is usually defined as an infection that is identified at least forty-eight to seventy-two hours ...

The U.S. Sleep Market by Marketdata Enterprises Inc.
Of a total population of 305 million Americans, 58% are estimated to experience insomnia symptoms or sleep disorders. Companies across America are trying to sell ...

See all reports like this >>

More United States Reports

e-Discovery Software Publishing in the US - Industry Market Research Report by IBISWorld
e-Discovery Software Publishing in the US Finding growth : Electronic discovery (more often known as e-discovery) refers to a data search, location and securing process for use ...

D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country Report: The United States of America by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Country Report United States January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

Coal - US - a snapshot (2010) by Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...

See all reports like this >>

U.S. Pulmonary Arterial Hypertension Markets

Share this report

Other tasks

Research Assistance

Related Markets

Respiratory/Pulmonary Reports

Free Alert Me service